Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biolojic Design

- PMLiVE

Researchers identify early treatment strategy for diabetic patients at risk of kidney disease

The chronic disease is currently the leading cause of kidney failure in the UK

- PMLiVE

Novo Nordisk’s Awiqli receives CHMP recommendation to treat diabetes in adults

The chronic disease is estimated to affect 415 million people worldwide

- PMLiVE

Eli Lilly shares positive late-stage results for lebrikizumab in atopic dermatitis

The study evaluated lebrikizumab in patients with moderate-to-severe AD and darker skin tones

- PMLiVE

New type of inhibitor drug could prevent microvascular diabetic complications

The drug could prevent conditions including diabetic eye and kidney disease in diabetes

- PMLiVE

Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn

The company will gain access to a portfolio of incretin-based therapies for diabetes and obesity

- PMLiVE

Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas

Approximately 18,740 new cases of CLL have been diagnosed in the US this year

- PMLiVE

Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m

The partnership is aimed at discovering oral inhibitors of a PPI target selected by Lilly

- PMLiVE

Eli Lilly to expand injectable manufacturing capacity with new $2.5bn facility in Germany

The site is expected to be operational in 2027 and will employ up to 1,000 highly skilled workers

- PMLiVE

Almirall granted EC approval for Ebglyss in moderate-to-severe atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

- PMLiVE

Eli Lilly’s tirzepatide injection approved by MHRA and FDA for weight loss in adults

The drug has been authorised for use alongside a reduced-calorie diet and physical activity

- PMLiVE

Eli Lilly exercises option to progress autoimmune and inflammatory disease therapy

The move triggers an undisclosed milestone payment to Lilly’s partner Sitryx Therapeutics

- PMLiVE

Eli Lilly’s Omvoh granted FDA approval for ulcerative colitis

Inflammatory bowel disease is estimated to affect nearly one in every 100 people in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links